The Mechanisms of Luteolin in Treating COVID-19 Based on Bioinformatics Analysis and Molecular Docki

来源 :感染性疾病与免疫(英文) | 被引量 : 0次 | 上传用户:
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读

Luteolin is a natural flavonoid that has a variety of pharmacological activities, such as anti-inflammatory, anti-allergic, anti-bacterial, antiviral, apoptosis inhibition, cell autophagy regulation, and anti-tumor activity. It is one of the main ingredients of an expert-recommended herbal formula for the prevention and treatment of coronavirus disease 2019 (COVID-19). This suggests that luteolin has strong pharmacological effects on the prevention and treatment of COVID-19. The aims of this study were to identify the molecular targets of luteolin and to infer the possible mechanisms by which it exerts its pharmacological effects. The GSE159787 data set was obtained from the Gene Expression Omnibus online database, and differentially expressed genes were analyzed. There were 22 upregulated differentially expressed genes enriched in the COVID-19 signaling pathway, suggesting that the upregulation of these genes may be closely related to the occurrence of COVID-19. Molecular docking results showed that luteolin had strong binding efficiency to 20 of these 22 key genes. Six of these genes (CFB, EIF2AK2, OAS1, MAPK11, OAS3, and STAT1) showed strong binding activity. Luteolin can regulate the COVID-19 signaling pathway by combining with these targets, which may have a therapeutic effect on COVID-19.

其他文献
哺乳动物雷帕霉素靶蛋白(mTOR)通路通过多种途径,参与调控细胞的生长发育、增殖迁移和存活自噬等过程。相关基因突变会导致mTOR通路过度激活,进而改变神经元的结构和功能,与癫痫等神经系统疾病相关。mTOR通路不同基因突变与各种临床表型存在一定联系,在不同的动物模型中均有验证。本文回顾总结了目前mTOR通路基因突变与癫痫的研究进展,并讨论基因突变与临床表型的相关性。
烧伤是常见的皮肤损伤,大面积烧伤给患者带来身体及心理的双重打击。近年来,越来越多的学者发现脂肪干细胞源性外泌体在促进创面愈合方面具有良好的应用前景,其本身无免疫原性、无致畸性等不良反应,比直接应用干细胞更为安全。本文通过阐述外泌体特征,脂肪干细胞源性外泌体修复烧伤创面机制及临床试验性研究,以期为烧伤创面修复提供新思路。